secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLOBUS MEDICAL INC (GMED)
CIK:        0001237831
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0001562762-21-000413
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Globus Medical Q3 2021 revenue up 6.3% to $229.7M; GAAP EPS $0.45, non-GAAP $0.50; FY guidance reaffirmed
--------------------------------------------------------------------------------

- Worldwide net sales $229.7M (+6.3% YoY); US sales +8.8%, International -7.2%.
- GAAP net income $47.2M (20.6% of sales); GAAP diluted EPS $0.45 vs $0.44; non-GAAP diluted EPS $0.50 vs $0.49.
- Non-GAAP adjusted EBITDA $78.3M (34.1% of sales); operating cash flow $77.3M; free cash flow $59.5M.
- Cash, equivalents and marketable securities $985M; debt-free. FY2021 guidance reaffirmed: net sales $950M, non-GAAP diluted EPS $2.00.
- CEO cites market share gains, Enabling Technology momentum, best recruiting quarter, and FDA clearances for Excelsius3D and ExcelsiusHUB.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1237831/000156276221000413/0001562762-21-000413-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1237831/000156276221000413/gmed-20211104x8k.htm
  HTML page:      https://secwatch.observer/filing/0001562762-21-000413

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer